JP7001584B2 - 安定化されたグルカゴン溶液 - Google Patents

安定化されたグルカゴン溶液 Download PDF

Info

Publication number
JP7001584B2
JP7001584B2 JP2018512193A JP2018512193A JP7001584B2 JP 7001584 B2 JP7001584 B2 JP 7001584B2 JP 2018512193 A JP2018512193 A JP 2018512193A JP 2018512193 A JP2018512193 A JP 2018512193A JP 7001584 B2 JP7001584 B2 JP 7001584B2
Authority
JP
Japan
Prior art keywords
glucagon
acid
composition
composition according
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018512193A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527358A (ja
JP2018527358A5 (enExample
Inventor
チェン，ハイリャン
シエン チェン，アンドリュー
キース オリダ，ノーマン
Original Assignee
ラティチュード ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラティチュード ファーマシューティカルズ インコーポレイテッド filed Critical ラティチュード ファーマシューティカルズ インコーポレイテッド
Publication of JP2018527358A publication Critical patent/JP2018527358A/ja
Publication of JP2018527358A5 publication Critical patent/JP2018527358A5/ja
Application granted granted Critical
Publication of JP7001584B2 publication Critical patent/JP7001584B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018512193A 2015-09-04 2016-09-02 安定化されたグルカゴン溶液 Active JP7001584B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214831P 2015-09-04 2015-09-04
US62/214,831 2015-09-04
PCT/US2016/050110 WO2017040928A1 (en) 2015-09-04 2016-09-02 Stabilized glucagon solutions

Publications (3)

Publication Number Publication Date
JP2018527358A JP2018527358A (ja) 2018-09-20
JP2018527358A5 JP2018527358A5 (enExample) 2019-10-17
JP7001584B2 true JP7001584B2 (ja) 2022-01-19

Family

ID=58188530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018512193A Active JP7001584B2 (ja) 2015-09-04 2016-09-02 安定化されたグルカゴン溶液

Country Status (6)

Country Link
US (1) US10888616B2 (enExample)
EP (1) EP3344231B1 (enExample)
JP (1) JP7001584B2 (enExample)
CN (1) CN107949374B (enExample)
CA (1) CA2995392C (enExample)
WO (1) WO2017040928A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949374B (zh) 2015-09-04 2022-04-08 莱迪杜德制药公司 稳定的胰高血糖素溶液
US11286433B2 (en) * 2017-08-01 2022-03-29 Gaps Technology, Llc Compositions and methods for remediating hydrogen sulfide in hydrocarbon based liquids
CN108174843B (zh) * 2018-01-24 2018-11-13 广州市进德生物科技有限公司 一种胰高血糖素保护剂及其应用
AU2019223659B2 (en) 2018-02-23 2024-09-05 F. Hoffmann-La Roche Ag Dosing unit refilling scheduling
TWI771669B (zh) * 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
WO2021168572A1 (en) * 2020-02-25 2021-09-02 Kane Biotech Inc. Stable liquid dispersinb compositions
TW202239427A (zh) * 2020-12-22 2022-10-16 美商美國禮來大藥廠 治療肽調配物
US12128089B2 (en) * 2022-05-26 2024-10-29 Slayback Pharma Llc Stable liquid compositions of glucagon

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501707A (ja) 2010-11-03 2014-01-23 アレコー リミテッド グルカゴンを含む新規組成物
JP2015503565A (ja) 2011-12-29 2015-02-02 ラティチュード ファーマシューティカルズ インコーポレイテッドＬａｔｉｔｕｄｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 安定化させたグルカゴンナノエマルジョン

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1732012A (zh) * 2002-12-27 2006-02-08 迪奥贝克斯公司 用于预防和控制胰岛素诱发的低血糖的组合物和方法
JP2008505087A (ja) * 2004-06-29 2008-02-21 ディオベックス， インコーポレイテッド インスリン誘発性低血糖の予防および制御のための組成物ならびに方法
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
WO2011011675A1 (en) * 2009-07-23 2011-01-27 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
US9610329B2 (en) * 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
US20120046225A1 (en) * 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
CN105853348B (zh) * 2011-03-10 2019-08-30 Xeris药物公司 肠胃外注射用稳定溶液
CN103889442B (zh) * 2011-08-10 2016-12-28 阿道恰公司 至少一种基础胰岛素的可注射溶液
US9334316B2 (en) * 2014-04-11 2016-05-10 Oregon Health & Science University Formulations comprising glucagon
CN107106659B (zh) * 2014-10-27 2022-07-08 莱迪杜德制药公司 肠胃外胰高血糖素制剂
CN107949374B (zh) 2015-09-04 2022-04-08 莱迪杜德制药公司 稳定的胰高血糖素溶液

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501707A (ja) 2010-11-03 2014-01-23 アレコー リミテッド グルカゴンを含む新規組成物
JP2015503565A (ja) 2011-12-29 2015-02-02 ラティチュード ファーマシューティカルズ インコーポレイテッドＬａｔｉｔｕｄｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 安定化させたグルカゴンナノエマルジョン

Also Published As

Publication number Publication date
CN107949374B (zh) 2022-04-08
JP2018527358A (ja) 2018-09-20
US10888616B2 (en) 2021-01-12
EP3344231B1 (en) 2022-04-13
US20180236079A1 (en) 2018-08-23
EP3344231A4 (en) 2019-03-27
CN107949374A (zh) 2018-04-20
CA2995392A1 (en) 2017-03-09
WO2017040928A1 (en) 2017-03-09
EP3344231A1 (en) 2018-07-11
CA2995392C (en) 2023-08-15

Similar Documents

Publication Publication Date Title
JP7001584B2 (ja) 安定化されたグルカゴン溶液
US20240207365A1 (en) Methods for producing stable therapeutic formulations in aprotic polar solvents
CA2816114C (en) Novel composition comprising glucagon
US20140378381A1 (en) Stabilized glucagon nanoemulsions
WO2016196976A1 (en) Glucagon delivery apparatuses and related methods
US10238717B2 (en) Parenteral glucagon formulations
JP7444786B2 (ja) 低用量の安定なグルカゴンを使用する肥満治療手術後の低血糖症の処置
AU2018388417C1 (en) Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes
AU2018301715B2 (en) Methods for treating congenital hyperinsulinism
CN103826609A (zh) 凝胶组合物
HK40081665A (en) Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
HK1250644B (en) Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210909

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210909

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210921

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211105

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211224

R150 Certificate of patent or registration of utility model

Ref document number: 7001584

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250